Working… Menu

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01998035
Recruitment Status : Terminated (PI left institution)
First Posted : November 28, 2013
Last Update Posted : January 8, 2021
Information provided by (Responsible Party):
Columbia University